The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
 
Petros Christopoulos
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)
 
Miriam Blasi
No Relationships to Disclose
 
Dirk Eberhard
No Relationships to Disclose
 
Daniel Kazdal
No Relationships to Disclose
 
Teresa Romero Cruz
No Relationships to Disclose
 
Farastuk Bozorgmehr
Honoraria - AstraZeneca; Janssen; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
 
Rajiv Shah
Honoraria - AstraZeneca; Roche
Research Funding - Bristol Myers Squibb GmbH & Co.KGaA (Inst)
 
Florian Eichhorn
No Relationships to Disclose
 
Hauke Winter
Consulting or Advisory Role - AstraZeneca; Intuitive Surgical; Roche Pharma AG
Research Funding - AstraZeneca; Intuitive Surgical
Travel, Accommodations, Expenses - Intuitive Surgical
 
Jonas Kuon
Research Funding - AstraZeneca; Bristol-Myers Squibb
 
Jan Budczies
No Relationships to Disclose
 
Helge Bischoff
No Relationships to Disclose
 
Albrecht Stenzinger
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Illumina; Merck Sharp & Dohme; Novartis; Roche; Thermofisher Scientific Biomarkers
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst)
 
Michael Thomas
Honoraria - AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; Janssen; Lilly O.; Merck KGaA; Merck Sharp & Dohme
Speakers' Bureau - AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo Pharmaceutical; GlaxoSmithKline; Janssen; Lilly O.; Merck KGaA; Merck Sharp & Dohme
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Janssen Oncology; Lilly O.; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche